{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:36:26Z","timestamp":1790501786856,"version":"4.1.0"},"reference-count":82,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T00:00:00Z","timestamp":1571011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Pulmonology"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute\u00a0pulmonary exacerbations (APE) are a complication of cystic fibrosis (CF) and are associated with morbidity and mortality. Methicillin\u2010resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA) is one of many organisms that has been detected in the airways of patients with CF. This review provides an evidence\u2010based summary of pharmacokinetic\/pharmacodynamic (PK\/PD), tolerability, and efficacy studies utilizing anti\u2010MRSA antibiotics (ie, ceftaroline, clindamycin, fluoroquinolone derivatives (ciprofloxacin, levofloxacin), glycopeptide derivatives (telavancin, vancomycin), linezolid, rifampin, sulfamethoxazole\/trimethoprim (SMZ\/TMP), and tetracycline derivatives (doxycycline, minocycline, tigecycline) in the treatment of APE and identifies areas where further study is warranted. A recent utilization study of antimicrobials for anti\u2010MRSA has shown some CF Foundation accredited care centers and affiliate programs are using doses higher than the FDA\u2010approved doses. Further studies are needed to determine the PK\/PD properties in CF patients with clindamycin, minocycline, rifampin, SMZ\/TMP, telavancin, and tigecycline; as well as, efficacy and tolerability studies with ciprofloxacin, clindamycin, doxycycline, levofloxacin, minocycline, rifampin, SMZ\/TMP, in CF patients with MRSA.<\/jats:p>","DOI":"10.1002\/ppul.24537","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T10:29:20Z","timestamp":1571048960000},"page":"33-57","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["State of the art in cystic fibrosis pharmacology\u2014Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti\u2010methicillin\u2010resistant <i>Staphylococcus aureus<\/i> (MRSA) antibiotics"],"prefix":"10.1002","volume":"55","author":[{"given":"Quovadis J.","family":"Epps","sequence":"first","affiliation":[{"name":"Florida Agricultural and Mechanical University College of Pharmacy and Pharmaceutical Sciences  Jacksonville Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Epps","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Mayo Clinic  Jacksonville Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0977-7257","authenticated-orcid":false,"given":"David C.","family":"Young","sequence":"additional","affiliation":[{"name":"L.S. Skaggs Pharmacy Institute University of Utah College of Pharmacy  Salt Lake City Utah"},{"name":"University of Utah Adult Cystic Fibrosis Center  Salt Lake City Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6047-306X","authenticated-orcid":false,"given":"Jeffery T.","family":"Zobell","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Intermountain Primary Children's Hospital  Salt Lake City Utah"},{"name":"Primary Children's Cystic Fibrosis Center  Salt Lake City Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,10,14]]},"reference":[{"key":"e_1_2_7_1_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607183350307"},{"key":"e_1_2_7_1_3_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200304-505SO"},{"key":"e_1_2_7_1_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.22757"},{"key":"e_1_2_7_1_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23132"},{"key":"e_1_2_7_1_6_1","unstructured":"Forest Pharmaceuticals Inc. Teflaro approved package labeling. May2016."},{"key":"e_1_2_7_1_7_1","unstructured":"Akorn Inc. Clindamycin phosphate injection approved package labeling.2018."},{"key":"e_1_2_7_1_8_1","unstructured":"Greenstone LLC. Clindamycin hydrochloride capsule approved package labeling.\u00a02018."},{"key":"e_1_2_7_1_9_1","doi-asserted-by":"publisher","DOI":"10.4065\/74.8.825"},{"key":"e_1_2_7_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2009.06.008"},{"key":"e_1_2_7_1_11_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-2437"},{"key":"e_1_2_7_1_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.22815"},{"key":"e_1_2_7_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2007.07.010"},{"key":"e_1_2_7_1_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014567526"},{"key":"e_1_2_7_1_15_1","unstructured":"Bayer HealthCare Pharmaceuticals Inc. Cipro approved package labeling.July 2016."},{"issue":"214","key":"e_1_2_7_1_16_1","article-title":"Optimizing antibiotic pharmacodynamics for clinical practice","volume":"4","author":"Connors KP","year":"2013","journal-title":"Pharmaceut Anal Acta"},{"key":"e_1_2_7_1_17_1","unstructured":"Janssen Pharmaceuticals Inc. Levaquin approved package labeling. July2018."},{"key":"e_1_2_7_1_18_1","unstructured":"Theravance Biopharma Antibiotics Inc. Vibativ approved package labeling.May 2016."},{"key":"e_1_2_7_1_19_1","unstructured":"Baxter Healthcare Corporation. Vancomycin approved package labeling.December 2015."},{"key":"e_1_2_7_1_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir034"},{"key":"e_1_2_7_1_21_1","unstructured":"Pharmacia and Upjohn LL. Zyvox approved package labeling.February 2018."},{"key":"e_1_2_7_1_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20966"},{"key":"e_1_2_7_1_23_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a027011"},{"key":"e_1_2_7_1_24_1","unstructured":"Mylan Institutional LLC. Rifampin injection approved package labeling.2018."},{"key":"e_1_2_7_1_25_1","unstructured":"Eon Labs Inc. Rifampin capsule approved package labeling.2019."},{"key":"e_1_2_7_1_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2118-2124.2003"},{"key":"e_1_2_7_1_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01520-08"},{"key":"e_1_2_7_1_28_1","unstructured":"Sun Pharmaceutical Industries Inc. Sulfamethoxazole and trimethoprim tablet approve package labeling.2018."},{"key":"e_1_2_7_1_29_1","unstructured":"Mylan Institutional LLC. Sulfamethoxazole and trimethoprim injection.2018."},{"key":"e_1_2_7_1_30_1","doi-asserted-by":"publisher","DOI":"10.4065\/74.7.730"},{"key":"e_1_2_7_1_31_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198224060-00002"},{"key":"e_1_2_7_1_32_1","doi-asserted-by":"publisher","DOI":"10.1086\/320532"},{"key":"e_1_2_7_1_33_1","doi-asserted-by":"publisher","DOI":"10.1086\/315148"},{"key":"e_1_2_7_1_34_1","unstructured":"Roerig. Vibramycin injection approved package labeling.July 2017."},{"key":"e_1_2_7_1_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.65.2.232-260.2001"},{"key":"e_1_2_7_1_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/000992287701600110"},{"key":"e_1_2_7_1_37_1","unstructured":"Wyeth Pharmaceuticals LLC. Tygacil approved package labeling.April 2018."},{"key":"e_1_2_7_1_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2017.10.010"},{"key":"e_1_2_7_1_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1681"},{"key":"e_1_2_7_1_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.47.548.366"},{"key":"e_1_2_7_1_41_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.1.186"},{"key":"e_1_2_7_1_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1320"},{"key":"e_1_2_7_1_43_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R272"},{"key":"e_1_2_7_1_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23844"},{"key":"e_1_2_7_1_45_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-23.2.125"},{"key":"e_1_2_7_1_46_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-21.2.155"},{"key":"e_1_2_7_1_47_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp150605"},{"key":"e_1_2_7_1_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1061"},{"key":"e_1_2_7_1_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh072"},{"key":"e_1_2_7_1_50_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.281-284.2004"},{"key":"e_1_2_7_1_51_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01797-10"},{"key":"e_1_2_7_1_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(84)81019-7"},{"key":"e_1_2_7_1_53_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05710-11"},{"key":"e_1_2_7_1_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.10.004"},{"key":"e_1_2_7_1_55_1","unstructured":"Cystic Fibrosis Trust. Antibiotic treatment for cystic fibrosis. Cystic Fibrosis Trust Antibiotic Working Group.2009."},{"key":"e_1_2_7_1_56_1","unstructured":"Pfizer Labs. Vibramycin oral approved package labeling.August 2017."},{"key":"e_1_2_7_1_57_1","unstructured":"Rempex Pharmaceuticals Inc. Minocin injection approved package labeling.June 2018."},{"key":"e_1_2_7_1_58_1","unstructured":"Patheon Pharmaceuticals Inc. Minocin capsule approved package labeling.August 2010."},{"key":"e_1_2_7_1_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23827"},{"issue":"2","key":"e_1_2_7_1_60_1","first-page":"135","article-title":"Ceftaroline fosamil for methicillin\u2010resistant Staphylococcus aureus pulmonary exacerbation in a pediatric cystic fibrosis patient","volume":"19","author":"Molloy L","year":"2014","journal-title":"J Pediatr Pharmacol Ther"},{"key":"e_1_2_7_1_61_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001171"},{"key":"e_1_2_7_1_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1323"},{"key":"e_1_2_7_1_63_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03622-14"},{"key":"e_1_2_7_1_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(81)80282-X"},{"key":"e_1_2_7_1_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2017.01.006"},{"key":"e_1_2_7_1_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.10062"},{"key":"e_1_2_7_1_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2003.12.010"},{"key":"e_1_2_7_1_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.03.012"},{"key":"e_1_2_7_1_69_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01308-10"},{"key":"e_1_2_7_1_70_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00208-13"},{"key":"e_1_2_7_1_71_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01392-13"},{"key":"e_1_2_7_1_72_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02067-15"},{"issue":"4","key":"e_1_2_7_1_73_1","first-page":"e163","article-title":"Linezolid\u2010resistant Staphylococcus aureus in children with cystic fibrosis","volume":"4","author":"Yu D","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"key":"e_1_2_7_1_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp494"},{"key":"e_1_2_7_1_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw108"},{"key":"e_1_2_7_1_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.11.008"},{"key":"e_1_2_7_1_77_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-22.6.406"},{"key":"e_1_2_7_1_78_1","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2017.0162"},{"key":"e_1_2_7_1_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000714"},{"key":"e_1_2_7_1_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.06.002"},{"key":"e_1_2_7_1_81_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140050-00002"},{"key":"e_1_2_7_1_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23505"},{"key":"e_1_2_7_1_83_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit270"}],"container-title":["Pediatric Pulmonology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.24537","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ppul.24537","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.24537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T23:27:07Z","timestamp":1694129227000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ppul.24537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,14]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1002\/ppul.24537"],"URL":"https:\/\/doi.org\/10.1002\/ppul.24537","archive":["Portico"],"relation":{},"ISSN":["8755-6863","1099-0496"],"issn-type":[{"value":"8755-6863","type":"print"},{"value":"1099-0496","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,14]]},"assertion":[{"value":"2019-05-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}